Drugs / FC084CSA
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06231550 | Mar 2023 → Mar 2025 | cancer | FindCure Biosciences (ZhongShan) Co., Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06499350 | Nov 2024 → Jul 2026 overdue | cancer | FindCure Biosciences (ZhongShan) Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FC084CSA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06499350 ↗ |
| Action | Inhibit | “Axl inhibitor FC084CSA” NCT06231550 ↗ |
| Target | AXL | “Axl inhibitor FC084CSA” NCT06231550 ↗ |